Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China.
Int J Mol Sci. 2024 Oct 3;25(19):10668. doi: 10.3390/ijms251910668.
Cognitive impairment is a core feature of schizophrenia, playing a pivotal role in the pathogenesis and prognosis of this disorder. Cognitive impairment in schizophrenia encompasses a wide range of domains, including processing speed, episodic memory, working memory, and executive function. These deficits persist throughout the course of the illness and significantly impact functional outcomes and quality of life. Therefore, it is imperative to identify the biological basis of cognitive deficits in schizophrenia and develop effective treatments. The role of N-methyl-D-aspartate (NMDA) receptors in synaptic transmission and plasticity has long been recognized, making them potential targets for schizophrenia treatment. This review will focus on emerging pharmacology targeting NMDA receptors, offering strategies for the prevention and treatment of cognitive deficits in schizophrenia.
认知障碍是精神分裂症的核心特征，在这种疾病的发病机制和预后中起着关键作用。精神分裂症的认知障碍包括广泛的领域，包括处理速度、情景记忆、工作记忆和执行功能。这些缺陷在疾病过程中持续存在，严重影响功能结果和生活质量。因此，确定精神分裂症认知缺陷的生物学基础并开发有效的治疗方法至关重要。N-甲基-D-天冬氨酸（NMDA）受体在突触传递和可塑性中的作用早已得到认可，使它们成为精神分裂症治疗的潜在靶点。本综述将重点介绍针对 NMDA 受体的新兴药理学，为精神分裂症认知缺陷的预防和治疗提供策略。
